Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IVL5007
- Development stage
- Preclinical
- Lead developer
- Inventage Lab
- Modality
- Peptides
- Administration
- Subcutaneous, Intramuscular
01
Overview
IVL5007 is a preclinical-stage long-acting injectable (LAI) peptide formulation developed by Inventage Lab in collaboration with Boehringer Ingelheim. The candidate utilizes Inventage Lab's proprietary IVL-DrugFlow platform, a microsphere-based drug delivery technology designed to provide sustained release of peptide therapeutics. By encapsulating the peptide in biodegradable polymer microspheres, the formulation aims to maintain stable blood concentrations and reduce dosing frequency compared to conventional peptide administrations. The specific therapeutic target and indication for IVL5007 are currently undisclosed.
Beyond the preview
Go deeper on IVL5007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IVL5007.